Claims:

1. A composition comprising one or more RNAi agents, wherein the one or more RNAi agents comprise:

(a) an antisense strand comprising a nucleotide sequence of any one of the following: SEQ ID NO:100, SEQ ID NO:126, SEQ ID NO:127, SEQ ID NO:128, SEQ ID NO:171, SEQ ID NO:179 and SEQ ID NO:180; and

(b) a sense strand comprising a nucleotide sequence of any one of the following: SEQ ID NO:229, SEQ ID NO:252, SEQ ID NO:253, SEQ ID NO:273, SEQ ID NO:302 and SEQ ID NO:319.

2. The composition of claim 1, wherein the one or more RNAi agents comprise at least one modified nucleotide or at least one modified inter-nucleoside linkage.

3. The composition of claim 1 or 2, wherein substantially all of the nucleotides in the one or more RNAi agents are modified nucleotides.

4. The composition of any one of claims 1-3, wherein the one or more RNAi agents further comprise a targeting ligand that is conjugated to the one or more RNAi agents.

5. The composition of claim 4, wherein the targeting ligand comprises N-acetyl-galactosamine.

6. The composition of claim 5, wherein the targeting ligand comprises an N-acetyl-galactosamine trimer or an N-acetyl-galactosamine tetramer.

7. The composition of claim 6, wherein the targeting ligand is selected form the group consisting of (NAG13), (NAG13)s, (NAG18), (NAG18)s, (NAG24), (NAG24)s, (NAG25), (NAG25)s, (NAG26), (NAG26)s, (NAG27), (NAG27)s, (NAG28), (NAG28)s, (NAG29), (NAG29)s, (NAG30), (NAG30)s, (NAG31), (NAG31)s, (NAG32), (NAG32)s, (NAG33), (NAG33)s,

(NAG34), (NAG34)s, (NAG35), (NAG35)s, (NAG36), (NAG36)s, (NAG37), (NAG37)s, (NAG38), (NAG38)s, (NAG39), and (NAG39)s.

8. The composition of claim 7, wherein the targeting ligand is (NAG25), (NAG25)s, (NAG31), (NAG31)s, (NAG37), or (NAG37)s.

9. The composition of any one of claims 4-8, wherein the targeting ligand is conjugated to the sense strand of the one or more RNAi agents.

10. The composition of any one of claims 4-8, wherein the targeting ligand is conjugated to the antisense strand of the one or more RNAi agents.

11. The composition of claim 9, wherein the targeting ligand is conjugated to the 5' terminus of the sense strand of the one or more RNAi agents.

12. The composition of claim 9, wherein the targeting ligand is conjugated to the 3' terminus of the sense strand of the one or more RNAi agents.

13. The composition of claim 10, wherein the targeting ligand is conjugated to the 3' terminus of the antisense strand of the one or more RNAi agents.

14. The composition of any one of claims 1-13, wherein the sense strand further comprises one or more inverted abasic nucleosides.

15. The composition of any one of claims 1-14 further comprising a pharmaceutically acceptable excipient, carrier, or diluent.

16. The composition of any one of claims 1-14 further comprising an additional RNAi agent, wherein the additional RNAi agent comprises: an antisense strand comprising a nucleotide sequence of any one of the following: SEQ ID NO:140, SEQ ID NO:137, SEQ ID NO:102, SEQ ID NO:162 and SEQ ID NO:188, and a sense strand comprising a nucleotide sequence of any

one of the following: SEQ ID NO:248, SEQ ID NO:294, SEQ ID NO:262, SEQ ID NO:271, SEQ ID NO:274, and SEQ ID NO:328.

17. The composition of claim 16, wherein the composition comprises two or more RNAi agents independently selected from the group consisting of: AD04571 (SEQ ID NO: 100 and SEQ ID NO:229), AD04776 (SEQ ID NO: 102 and SEQ ID NO:248), AD04872 (SEQ ID NO: 126 and SEQ ID NO:252), AD04873 (SEQ ID NO: 127 and SEQ ID NO:252), AD04874 (SEQ ID NO: 128 and SEQ ID NO:253), AD04982 (SEQ ID NO: 137 and SEQ ID NO:248), AD05070 (SEQ ID NO:140 and SEQ ID NO:262), AD05148 (SEQ ID NO:140 and SEQ ID NO:271), AD05164 (SEQ ID NO:126 and SEQ ID NO:273) and AD05165 (SEQ ID NO:140 and SEQ ID NO:274).

18. The composition of claim 16, wherein the ratio of the one or more RNAi agents to the additional RNAi agent by weight is in the range of about 1:2 to about 5:1.

19. The composition of claim 18, wherein the ratio of the one or more RNAi agents to the additional RNAi agent by weight is about 2:1 or about 3:1.

20. The composition of claim 19, wherein the one or more RNAi agents comprise an antisense strand comprising SEQ ID NO: 126 and a sense strand comprising SEQ ID NO: 252, the additional RNAi agent comprises an antisense strand comprising SEQ ID NO: 140 and a sense strand comprising SEQ ID NO: 262.

21. The composition of claim 19, wherein the one or more RNAi agents comprise an antisense strand comprising SEQ ID NO: 126 and a sense strand comprising SEQ ID NO: 252, the additional RNAi agent comprises an antisense strand comprising SEQ ID NO:102 and a sense strand comprising SEQ ID NO: 248.

22. The composition of claim 19, wherein the one or more RNAi agents comprise an antisense strand comprising SEQ ID NO: 126 and a sense strand comprising SEQ ID NO: 252, the additional RNAi agent comprises an antisense strand comprising SEQ ID NO:137 and a sense strand comprising SEQ ID NO: 248.

23. The composition of claim 17, wherein the two or more RNAi agents are each independently conjugated to a targeting ligands comprising N-acetyl-galactosamine.

24. The composition of any one of claims 18-23, wherein the sense strand of the one or more RNAi agents or the additional RNAi agent further comprises one or more inverted abasic nucleosides.

25. A pharmaceutical composition comprising the composition of any one of claims 67-90 and a pharmaceutically acceptable excipient, carrier, or diluent.

26. A kit comprising the pharmaceutical composition of claim 25.

27. The kit of claim 26 further comprising a syringe or a vial.

28. A composition comprising one or more RNAi agents, wherein the one or more RNAi agents comprise:

(a) an antisense strand comprising a nucleotide sequence of any one of the following: SEQ ID NO:140, SEQ ID NO:102, SEQ ID NO:137, SEQ ID NO:162 and SEQ ID NO:188; and

(b) a sense strand comprising a nucleotide sequence of any one of the following: SEQ ID NO:248, SEQ ID NO:294, SEQ ID NO:262, SEQ ID NO:271, SEQ ID NO:274, and SEQ ID NO:328.

29. The composition of claim 28, wherein the one or more RNAi agents comprise at least one modified nucleotide or at least one modified inter-nucleoside linkage.

30. The composition of claim 28 or 29, wherein substantially all of the nucleotides in the one or more RNAi agents are modified nucleotides.

31. The composition of any one of claims 28-30, wherein the one or more RNAi agents further comprise a targeting ligand that is conjugated to the one or more RNAi agents.

32. The composition of claim 31, wherein the targeting ligand is selected form the group consisting of (NAG13), (NAG13)s, (NAG18), (NAG18)s, (NAG24), (NAG24)s, (NAG25), (NAG25)s, (NAG26), (NAG26)s, (NAG27), (NAG27)s, (NAG28), (NAG28)s, (NAG29), (NAG29)s, (NAG30), (NAG30)s, (NAG31), (NAG31)s, (NAG32), (NAG32)s, (NAG33), (NAG33)s, (NAG34), (NAG34)s, (NAG35), (NAG35)s, (NAG36), (NAG36)s, (NAG37), (NAG37)s, (NAG38), (NAG38)s, (NAG39), and (NAG39)s.

33. The composition of claim 31 or 32, wherein the targeting ligand is conjugated to the sense strand of the one or more RNAi agents.

34. The composition of claim 31 or 32, wherein the targeting ligand is conjugated to the antisense strand of the one or more RNAi agents.

35. The composition of any one of claims 28-34, wherein the sense strand further comprises one or more inverted abasic nucleosides.

36. A pharmaceutical composition comprising the composition of any one of claims 28-35 and a pharmaceutically acceptable excipient, carrier, or diluent.

37. A kit comprising the pharmaceutical composition of claim 36.

38. Use of an effective amount of the composition according to any one of claims 1-24 in the manufacture of a medicament for reducing or inhibiting the expression of at least one Hepatitis B Virus gene in a subject in need thereof, wherein the medicament is to be administered to the subject.

39. The use of claim 38, wherein the composition is to be administered in the amount of about 0.25-5 mg/kg.

40. The use of claim 38 or 39, wherein the composition is formulated for subcutaneous or intravenous injection.

41. The use of any one of claims 38-40, wherein one or more additional therapeutics are to be administered to the subject.

42. The use of claim 41, wherein the additional therapeutic is lamivudine, tenofovir, tenofovir alafenamide, tenofovir disoproxil, or entecavir.

43. Use of an effective amount of the composition according to any one of claims 1-24 in the manufacture of a medicament for the treatment of a disease or disorder associated with Hepatitis B Virus infection in a subject in need thereof, wherein the medicament is to be administered to the subject.

44. The use of claim 43, wherein the composition is to be administered in the amount of about 0.25-5 mg/kg.

45. The use of claim 43 or 44, wherein the composition is formulated for subcutaneous or intravenous injection.

46. The use of any one of claims 43-45, wherein the subject has an infection caused by the Hepatitis B Virus.

47. The use of any one of claims 43-46, wherein one or more additional therapeutics are to be administered to the subject.

48. The use of claim 47, wherein the additional therapeutic is lamivudine, tenofovir, tenofovir alafenamide, tenofovir disoproxil, or entecavir.

49. A combination of at least two RNAi agents comprising a first RNAi agent and a second RNAi agent, wherein:

(a) the first RNAi agent comprising: an antisense strand comprising a nucleotide sequence of any one of the following: SEQ ID NO:100, SEQ ID NO:126, SEQ ID NO:127, SEQ ID NO:128, SEQ ID NO:171, SEQ ID NO:179, and SEQ ID NO:180, and a sense strand comprising a nucleotide sequence of any one of the following: SEQ ID NO:229, SEQ ID NO:252, SEQ ID NO:253, SEQ ID NO:273, SEQ ID NO:302, and SEQ ID NO:319; and

(b) the second RNAi agent comprising: an antisense strand comprising a nucleotide sequence of any one of the following: SEQ ID NO:140, SEQ ID NO:102, SEQ ID NO:137, SEQ ID NO:162 and SEQ ID NO:188, and a sense strand comprising a nucleotide sequence of any one of the following: SEQ ID NO:248, SEQ ID NO:294, SEQ ID NO:262, SEQ ID NO:271, SEQ ID NO:274, and SEQ ID NO:328.

50. The combination of claim 49, wherein the first or the second RNAi agent comprises at least one modified nucleotide or at least one modified inter-nucleoside linkage.

51. The combination of claim 49 or 50, wherein the first or the second RNAi agent further comprises a targeting ligand that is conjugated to the first or the second RNAi agent.

52. The combination of claim 51, wherein the targeting ligand is selected form the group consisting of (NAG13), (NAG13)s, (NAG18), (NAG18)s, (NAG24), (NAG24)s, (NAG25), (NAG25)s, (NAG26), (NAG26)s, (NAG27), (NAG27)s, (NAG28), (NAG28)s, (NAG29), (NAG29)s, (NAG30), (NAG30)s, (NAG31), (NAG31)s, (NAG32), (NAG32)s, (NAG33), (NAG33)s, (NAG34), (NAG34)s, (NAG35), (NAG35)s, (NAG36), (NAG36)s, (NAG37), (NAG37)s, (NAG38), (NAG38)s, (NAG39), and (NAG39)s.

53. The combination of claim 51 or 52, wherein the targeting ligand is conjugated to the 3' or 5' terminus of the sense strand of the one or more RNAi agents.

54. The combination of any one of claims 49-53, wherein the sense strand in the first or the second RNAi agents further comprises one or more inverted abasic nucleosides.

55. The combination of any one of claims 49-54 further comprising a pharmaceutically acceptable excipient, carrier, or diluent.

56. The combination of any one of claims 49-55, wherein the ratio of the first RNAi agent to the second RNAi agent by weight is in the range of about 1:2 to about 5:1.

57. The combination of any one of claims 49-56, wherein the first and the second RNA agents are formulated in a single pharmaceutical composition.

58. The combination of any one of claims 49-56, wherein the first and the second RNA agents are formulated in separate pharmaceutical compositions.

59. The combination of any one of claims 49-58, wherein the first and the second RNA agents are formulated for subcutaneous or intravenous injection.

60. A cell, tissue or non-human organism comprising the composition according to any one of claims 1-24.

61. A method of preparing an RNAi agent comprising conjugating a targeting group to a reactive group at the 5'- or 3'- terminus of the RNAi agent, wherein:

the RNAi agent comprises: (a) an antisense strand comprising a nucleotide sequence of any one of the following: SEQ ID NO:100, SEQ ID NO:126, SEQ ID NO:127, SEQ ID NO:128, SEQ ID NO:171, SEQ ID NO:179 and SEQ ID NO:180; and (b) a sense strand comprising a nucleotide sequence of any one of the following: SEQ ID NO:229, SEQ ID NO:252, SEQ ID NO:253, SEQ ID NO:273, SEQ ID NO:302 and SEQ ID NO:319;

the reactive group at the 5'- or 3'- terminus of the RNAi agent is selected from the group consisting of amine, alkyne, alkyl, abasic nucleoside, ribitol and PEG; and

the targeting group comprises N-acetyl-galactosamine.

62. The method of claim 61, wherein the reactive group is an amine.

63. The method of claim 60 or 61, wherein the targeting group is selected from the group consisting of (NAG13), (NAG13)s, (NAG18), (NAG18)s, (NAG24), (NAG24)s, (NAG25), (NAG25)s, (NAG26), (NAG26)s, (NAG27), (NAG27)s, (NAG28), (NAG28)s, (NAG29), (NAG29)s, (NAG30), (NAG30)s, (NAG31), (NAG31)s, (NAG32), (NAG32)s, (NAG33), (NAG33)s, (NAG34), (NAG34)s, (NAG35), (NAG35)s, (NAG36), (NAG36)s, (NAG37), (NAG37)s, (NAG38), (NAG38)s, (NAG39), and (NAG39)s.

64. The method of any one of claims 61-63, wherein the sense strand further comprises one or more inverted abasic nucleosides.